TFMFly
TFMFly, or TFM-FLY, is a drug related of the phenethylamine, DOx, and FLY families related to psychedelics like 2C-B-FLY and 2C-TFM. It was first reported in 2005 by a team at Purdue University led by David E. Nichols. It acts as a potent agonist at the 5HT2A serotonin receptor subtype, and is a chiral compound with the more active enantiomer having a Ki of 0.12 nM at the human 5-HT2A receptor. While the fully aromatic benzodifurans such as Bromo-DragonFLY generally have higher binding affinity than saturated compounds like 2C-B-FLY, the saturated compounds have higher efficacy as agonists.